OBJECTIVE: The purpose of this study was to evaluate atomoxetine treatment effects in attention-deficit/hyperactivity disorder (ADHD-only), attention-deficit/hyperactivity disorder with comorbid dyslexia (ADHD+D), or dyslexia only on ADHD core symptoms and on sluggish cognitive tempo (SCT), working memory, life performance, and self-concept. METHODS:Children and adolescents (10-16 years of age) with ADHD+D (n=124), dyslexia-only (n=58), or ADHD-only (n=27) receivedatomoxetine (1.0-1.4 mg/kg/day) orplacebo (ADHD-only subjects received atomoxetine) in a 16 week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only). Changes from baseline were assessed to weeks 16 and 32 in ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv); ADHD Rating Scale-IV-Teacher-Version (ADHDRS-IV-Teacher-Version); Life Participation Scale-Child- or Parent-Rated Version (LPS); Kiddie-Sluggish Cognitive Tempo (K-SCT) Interview; Multidimensional Self Concept Scale (MSCS); and Working Memory Test Battery for Children (WMTB-C). RESULTS: At week 16, atomoxetine treatment resulted in significant (p<0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. At Week 32, atomoxetine-treated ADHD+D subjects significantly improved from baseline on all measures except MSCS Family subscale and WMTB-C Central Executive and Visuo-spatial Sketchpad component scores. The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. The atomoxetine-treated ADHD-only subjects significantly improved from baseline to Week 32 on ADHDRS-Parent:Inv Total and subscales, ADHDRS-IV-Teacher-VersionHyperactive/Impulsive subscale, LPS Self-Control and Total, all K-SCT subscales, and MSCS Academic and Competence subscale scores. CONCLUSIONS:Atomoxetine treatment improved ADHD symptoms in subjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD. This is the first study to report significant effects of any medication on SCT. CLINICAL TRIALS REGISTRATION: This study was registered at: http://clinicaltrials.gov/ct2/home, NCT00607919.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate atomoxetine treatment effects in attention-deficit/hyperactivity disorder (ADHD-only), attention-deficit/hyperactivity disorder with comorbid dyslexia (ADHD+D), or dyslexia only on ADHD core symptoms and on sluggish cognitive tempo (SCT), working memory, life performance, and self-concept. METHODS:Children and adolescents (10-16 years of age) with ADHD+D (n=124), dyslexia-only (n=58), or ADHD-only (n=27) received atomoxetine (1.0-1.4 mg/kg/day) or placebo (ADHD-only subjects received atomoxetine) in a 16 week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only). Changes from baseline were assessed to weeks 16 and 32 in ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv); ADHD Rating Scale-IV-Teacher-Version (ADHDRS-IV-Teacher-Version); Life Participation Scale-Child- or Parent-Rated Version (LPS); Kiddie-Sluggish Cognitive Tempo (K-SCT) Interview; Multidimensional Self Concept Scale (MSCS); and Working Memory Test Battery for Children (WMTB-C). RESULTS: At week 16, atomoxetine treatment resulted in significant (p<0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. At Week 32, atomoxetine-treated ADHD+D subjects significantly improved from baseline on all measures except MSCS Family subscale and WMTB-C Central Executive and Visuo-spatial Sketchpad component scores. The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. The atomoxetine-treated ADHD-only subjects significantly improved from baseline to Week 32 on ADHDRS-Parent:Inv Total and subscales, ADHDRS-IV-Teacher-Version Hyperactive/Impulsive subscale, LPS Self-Control and Total, all K-SCT subscales, and MSCS Academic and Competence subscale scores. CONCLUSIONS:Atomoxetine treatment improved ADHD symptoms in subjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD. This is the first study to report significant effects of any medication on SCT. CLINICAL TRIALS REGISTRATION: This study was registered at: http://clinicaltrials.gov/ct2/home, NCT00607919.
Authors: Cara B Reeves; Shawna Palmer; Alan M Gross; Susan J Simonian; Lloyd Taylor; Elizabeth Willingham; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-10-12
Authors: Erik G Willcutt; Rebecca S Betjemann; Lauren M McGrath; Nomita A Chhabildas; Richard K Olson; John C DeFries; Bruce F Pennington Journal: Cortex Date: 2010-07-01 Impact factor: 4.027
Authors: Erik G Willcutt; Bruce F Pennington; Richard K Olson; John C DeFries Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-09-05 Impact factor: 3.568
Authors: Christien G W de Jong; Séverine Van De Voorde; Herbert Roeyers; Ruth Raymaekers; Albert J Allen; Simone Knijff; Helene Verhelst; Alfons H Temmink; Leo M E Smit; Rob Rodriques-Pereira; Dirk Vandenberghe; Inge van Welsen; Liesbeth ter Schuren; Mazim Al-Hakim; Azad Amin; Laurens Vlasveld; Jaap Oosterlaan; Joseph A Sergeant Journal: J Child Adolesc Psychopharmacol Date: 2009-12 Impact factor: 2.576
Authors: Stephen P Becker; Daniel R Leopold; G Leonard Burns; Matthew A Jarrett; Joshua M Langberg; Stephen A Marshall; Keith McBurnett; Daniel A Waschbusch; Erik G Willcutt Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-23 Impact factor: 8.829
Authors: Trevor W K Yung; Cynthia Y Y Lai; Jacob Y C Chan; Shamay S M Ng; Chetwyn C H Chan Journal: Eur Child Adolesc Psychiatry Date: 2019-05-27 Impact factor: 4.785
Authors: Tanya E Froehlich; Jason Fogler; William J Barbaresi; Nada A Elsayed; Steven W Evans; Eugenia Chan Journal: Clin Pharmacol Ther Date: 2018-08-30 Impact factor: 6.875
Authors: Madison M Berl; Virginia Terwilliger; Alexandra Scheller; Leigh Sepeta; Jenifer Walkowiak; William D Gaillard Journal: Epilepsia Date: 2015-05-04 Impact factor: 5.864
Authors: Stephen P Becker; Heather A Ciesielski; Jennifer E Rood; Tanya E Froehlich; Annie A Garner; Leanne Tamm; Jeffery N Epstein Journal: Clin Child Psychol Psychiatry Date: 2014-10-17 Impact factor: 2.544
Authors: Mark E Bangs; Linda A Wietecha; Shufang Wang; Andrew S Buchanan; Douglas K Kelsey Journal: J Child Adolesc Psychopharmacol Date: 2014-07-14 Impact factor: 2.576